Ensemble Discovery

company

About

Ensemble develops Ensemblins to treat diseases by addressing drug targets that are currently inaccessible with small molecule drugs.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$15M
Industries
Biotechnology,Health Care,Medical Device
Founded date
Jan 1, 2002
Number Of Employee
11 - 50
Operating Status
Active

Ensemble Discovery is developing a new class of therapeutics - the Ensemblinsâ„¢, orally bioavailable small molecule macrocyclic compounds that have the potential to behave like biologics and can disrupt protein-protein interactions. They have two complementary platforms that provide access to these molecules. Firstly, they use their proprietary DNA-Programmed Chemistryâ„¢ (DPCâ„¢) platform to generate hundreds of thousands of these molecules for rapid screening. Secondly, they have highly developed methods for the synthesis of Ensemblins as discrete molecules using conventional chemistry.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$30M
Ensemble Discovery has raised a total of $30M in funding over 2 rounds. Their latest funding was raised on Nov 12, 2007 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Nov 12, 2007 Series B $15M 2 Detail
May 12, 2004 Series A $15M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Ensemble Discovery is funded by 2 investors. ARCH Venture Partners and Aeneas Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series B
Aeneas Ventures Series B